Dialysis chain NephroPlus raises Rs 850 crores in Series F round from Quadria Capital
Advertisement
Hyderabad: Quadria Capital, an Asia\s healthcare-focused private equity firms, has announced an investment of INR 850 Crores in NephroPlus, Asia’s dialysis network.
Through this transaction, Quadria will acquire a significant minority stake through a combination of a primary investment and the purchase of shares from existing shareholders. The transaction will support NephroPlus in serving the growing demand for high quality, affordable dialysis services across India and other markets in Asia.
Founded in 2010, NephroPlus is a dialysis provider operating in sizeable, high-growth markets across Asia. The company serves patients across dialysis centres in marquee hospitals and at standalone clinics, working with leading nephrologists. NephroPlus also delivers care through public- private partnerships in both urban and rural areas.
Demand for dialysis services in the company’s target markets is expected to grow at a rate of over 11% annually over the next five years. Specialized chains such as NephroPlus are expected to gain market share as hospitals increasingly outsource dialysis operations and as governments seek to make high- quality dialysis services more accessible.
"With Quadria’s support, NephroPlus aims to leverage its strong brand, operational expertise, trusted relationships with leading nephrologists, to capitalise on growth opportunities and expand its market leadership," the release stated.
Vikram Vuppala, Founder and CEO of NephroPlus, said, “Our business has evolved tremendously over the past few years and today we are proud to be one of the fastest growing and most trusted providers of high-quality dialysis to around 30,000 patients. We look forward to expanding in India, our core market, while exploring further opportunities to bring our expertise and clinical excellence to more patients in other global markets. Quadria’s healthcare expertise, capital and focus on operational value creation will put us in an even better position to keep scaling, innovating, and delivering affordable and high-quality care.”
Sunil Thakur, Partner and Head of South Asia at Quadria Capital, said, “Quadria’s investment in NephroPlus underscores our ambition to invest in regional champions of Asian healthcare, who are providing high-quality, affordable healthcare to large, under-served populations. NephroPlus has demonstrated its ability to significantly improve health outcomes for its patients, whilst maintaining industry-leading growth and profitability. We look forward to working with their leadership team to continue to expand their footprint, increase access to dialysis services across Asia and accelerate the next phase of growth for NephroPlus.”
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.